Dataset Information

Symptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland.

ABSTRACT: (1) Background: To report and analyze the presence of residual symptoms after SARS-CoV-2 infection among Polish patients with multiple sclerosis (MS) treated with different disease-modifying therapies (DMTs). (2) Methods: The study included 426 individuals with MS treated with DMTs and confirmed SARS-CoV-2 infection from 12 Polish MS centers. The data were collected through to 31 May 2021. The information included demographics, specific MS characteristics, course of SARS-CoV-2 infection, and residual (general and neurological) symptoms lasting more than four and 12 weeks after the initial infection. The results were obtained using maximum likelihood estimates for odds ratio and logistic regression. (3) Results: A total of 44.84% patients with MS reported symptoms lasting between four and 12 weeks after the initial infection; 24.41% people had symptoms that resolved up to 12 weeks, and 20.42% patients had symptoms that lasted over 12 weeks. The most common symptoms were: fatigue, disturbance of concentration, attention, and memory, cognitive complaints, and headache. None of the DMTs were predisposed to the development of residual symptoms after the initial infection. A total of 11.97% of patients had relapse three months prior or after SARS-CoV-2 infection. (4) Conclusion: Almost half of individuals with MS treated with different DMTs had residual symptoms after SARS-CoV-2 infection. None of the DMTs raised the probability of developing post-acute COVID symptoms.

SUBMITTER: Czarnowska A

PROVIDER: S-EPMC8618380 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Symptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland.

Czarnowska Agata A Kapica-Topczewska Katarzyna K Zajkowska Olga O Adamczyk-Sowa Monika M Kubicka-Bączyk Katarzyna K Niedziela Natalia N Warmus Paweł P Kalinowska-Łyszczarz Alicja A Kania Karolina K Słowik Agnieszka A Wnuk Marcin M Marona Monika M Nowak Klaudia K Bartosik-Psujek Halina H Lech Beata B Perenc Adam A Popiel Małgorzata M Kucharska-Lipowska Marta M Chorąży Monika M Tarasiuk Joanna J Mirończuk Anna A Kochanowicz Jan J Lasek-Bal Anetta A Puz Przemysław P Maciejowska Katarzyna K Wawrzyniak Sławomir S Niezgodzińska-Maciejek Anna A Pokryszko-Dragan Anna A Gruszka Ewa E Budrewicz Sławomir S Białek Marta M Zwiernik Jacek J Michałowska Anna A Nosek Krzysztof K Zwiernik Beata B Lewańczyk Bożena B Brola Waldemar W Kułakowska Alina A

Journal of clinical medicine 20211110 22

(1) Background: To report and analyze the presence of residual symptoms after SARS-CoV-2 infection among Polish patients with multiple sclerosis (MS) treated with different disease-modifying therapies (DMTs). (2) Methods: The study included 426 individuals with MS treated with DMTs and confirmed SARS-CoV-2 infection from 12 Polish MS centers. The data were collected through to 31 May 2021. The information included demographics, specific MS characteristics, course of SARS-CoV-2 infection, and res ...[more]

PMID: 34830507

Similar Datasets

Project description:BackgroundThe outbreak of coronavirus disease 2019 (COVID-19) has rapidly spread and developed as a pandemic threatening global health. Patients with multiple sclerosis (MS)-an autoimmune demyelinating inflammatory disease of the central nervous system (CNS)-are predominantly treated with immunomodulatory/immunosuppressive disease-modifying therapies (DMTs), which can increase the risk of infection. Therefore, there is concern that these patients may have a higher risk of COVID-19. In response to growing concerns of neurologists and patients, this study aimed to determine the prevalence, severity, and possible complications of COVID-19 infection in patients with MS in Saudi Arabia (SA).MethodsIn this prospective cohort study, demographic and clinical data were obtained from patients residing in SA with MS who had a positive result for COVID-19 per reverse transcription-polymerase chain reaction test or viral gene sequencing, using respiratory or plasma samples. Comparison of COVID-19 severity groups was performed using one-way ANOVA or Kruskal-Wallis test for numerical variables and Chi-squared test for categorical variables.ResultsSeventy patients with MS and COVID-19 (71% female) were included in this analysis. Of the 53 (75.7%) patients receiving a DMT at the time of COVID-19 infection, the most frequently used DMTs were fingolimod (25%) and interferon-beta (25%). Nine (13%) patients had MS relapse and were treated with intravenous methylprednisolone in the four weeks before COVID-19 infection. The most common symptoms at the peak of COVID-19 infection were fever (46%), fatigue (37%), and headache (36%). Symptoms lasted for a mean duration of 8.7 days; all symptomatic patients recovered and no deaths were reported. COVID-19 severity was categorized in three groups: asymptomatic (n = 12), mild-not requiring hospitalization (n = 48), and requiring hospitalization (n = 10; two of whom were admitted to the intensive care unit [ICU]). Between the three groups, comparison of age, body mass index , Expanded Disability Severity Score , MS disease duration, and DMT use at the time of infection showed no significant differences. A higher percentage of patients who were admitted to hospital or the ICU (40%; p = 0.026) presented with an MS relapse within the prior four weeks compared with those who were asymptomatic or had a mild infection (both 8.3%).ConclusionThese findings present a reassuring picture regarding COVID-19 infection in patients with MS. However, patients with MS who have had a relapse in the preceding four weeks (requiring glucocorticoid treatment) may have an increased risk of severe COVID-19.

Dataset Information

Symptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland.

Publications

Symptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets